derives from the fact that no human cell types secrete significant amounts of PSA other than prostatic glandular cells or prostate cancer cells.
We now show that PSA converts Lys-plasminogen to biologically active angiostatin-like fragments by cleavage of a single peptide bond between kringle domains 4 and 5.
MATERIALS AND METHODS

Materials
PSA was purified from seminal plasma according to Zhang et al (1995) . Affinity absorption on Trasylol-Sepharose (Pharmacia) was added to the procedure according to Christensson et al (1990) in order to remove possible traces of kallikrein-like proteinases other than PSA from the preparation. Activity was monitored with MeO-Suc-Arg-Pro-Tyr-NA (S-2586, Chromogenix). PSA was electrophoretically pure and > 90% active. Identity and purity of PSA were confirmed by N-terminal amino acid sequencing. Electrophoretically pure human Lys-Plasminogen (Plasminogen HS, Activity >90%. Charge No. 281189) was kindly provided by Dr Römisch from the research department of Behringwerke (Marburg, Germany).
Proteolytic cleavage of plasminogen
To determine proteolysis of plasminogen by PSA, 3 µg of PSA were incubated with 50 µg plasminogen in 10 mM Tris-HCl, pH 8.0, in a final volume of 10 µl at 37°C. For time course analysis, samples were started individually at different times so as to reach their planned end points simultaneously, in order to avoid artefacts. At end point, all samples were immediately taken up in reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, boiled for 2 min and electrophoresed on 10% polyacrylamide gels (Laemmli, 1970) .
Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen Controls consisting of plasminogen and PSA alone were treated like the test samples. They showed no change after 6 h of incubation. For control purposes, PSA was inactivated by either 48-h exposure to 50 mM DFP (Sigma) or by boiling for 30 min. The inactivated preparations showed no detectable activity on MeO-Suc-Arg-Pro-Tyr-NA even after prolonged incubation (24 h).
N-terminal protein sequencing
For N-terminal amino acid sequencing of fragments, 30 µg of PSA were mixed with 500 µg of plasminogen in a final volume of 90 µl of 10 mM Tris-HCl, pH 8.0. After incubation at 37°C for 6 h, 90 µl of reducing SDS-sample buffer was added and the sample was boiled for 2 min. Finally, the material was applied to seven wells of a 10% PAGE gel, electrophoresed and blotted to a polyvinyldithioride (PVDF) membrane. After brief staining with Coomassie blue, the membrane was destained in 50% methanol, bands were cut out and pooled. The N-termini of the fragments were determined by automated Edman degradation using the Protein Sequencer 477A (Applied Biosystems).
Purification of angiostatin-like fragments
Angiostatin-like fragments were purified by lysine sepharose chromatography (Shi and Wu, 1988) . Three milligrams of plasminogen were digested with PSA for 20 h to completion as described above. The sample was then loaded onto a lysine sepharose column (Pharmacia) equilibrated with 10 mM Tris-HCl pH 8.0, and the flow-through was collected. Bound proteins were eluted with 200 mM ε-aminocaproic acid. Peak fractions were dialysed against phosphate-buffered saline (PBS), and the protein concentrations were determined photometrically. For controls, angiostatin was generated by elastase digestion of plasminogen according to O'Reilly et al (1996) .
In vitro morphogenesis assay
Human umbilical vein endothelial cells (HUVEC) were purchased from Cell-Systems (Clonetics). The cells were cultured in endothelial basal medium (EBM) supplemented with 2% brain extract (Clonetics). All experiments were performed with cells from passages 2-6, incubated at least overnight in EBM in absence of growth factor-containing brain extract. Matrigel (100 ml) diluted 1:2.5 with EBM containing 1 nM basic fibroblast growth factor (bFGF) (R&D) was added to each well of 24-culture plates at 4°C and then incubated at 37°C for 30 min to induce gelation. HUVEC (5 × 10 4 ) were then plated into each well in EBM with and without different stimulants. The cells were then incubated for 18 h at 37°C. Formation of tubes was evaluated first by phase contrast microscopy and second by cell counting after treatment of cells with dispase (Kumar et al, 1998) .
RESULTS
Incubation of Lys-plasminogen with PSA generated a set of three distinct fragments by limited proteolysis at 37°C. SDS-PAGE analysis of the time course of this reaction is shown in Figure 1 . The three major bands (a, b, and c), with apparent molecular masses of 44.5 kDa, 41 kDa and 38 kDa, appeared already after the first hour. With time, the intensity of these bands increased, while the band corresponding to plasminogen was diminished simultaneously. After prolonged incubation over 6 h, the fragments a, b, and c persisted without further degradation, whereas plasminogen was consumed almost completely. No cleavage of plasminogen was observed when active PSA was substituted by heat-inactivated PSA (Figure 2 ) or PSA inactivated with DFP (not shown).
In order to identify the cleavage sites, fragment bands were blotted onto PVDF membrane, cut out and analysed for their N-terminal amino acid sequences. As summarized in Figure 3 , both fragments a and b had the same N-termini (KVYLSEKK) starting with Lys78. A minor fraction within both fragments started with Val79, due to a common heterogeneity at this site (Wallén and Wiman, 1972) . Sequencing of fragment c (ASVVAPPPVV) indicated a cleavage site at Glu439-Ala440, located between kringles 4 and 5. Sequencing of the bands corresponding to Lys-plasminogen and PSA confirmed their identities.
Angiostatin-like fragments a and b were purified by lysine sepharose chromatography. Fragment c was found in the flowthrough, while fragments a and b bound to the resin and could be eluted with ε-aminocaproic acid (Figure 4 ). This finding further demonstrated that fragments a and b contain the kringle-like domains. In in vitro morphogenesis assays, fragments a and b inhibited tubular formation and proliferation of HUVECs with the same efficacy as elastase-generated angiostatin ( Figure 5 ). Halfmaximal inhibition in this assay was observed at a concentration of 1 µg ml -1 . Morphologic assessment by phase-contrast microscopy showed full inhibition of tubular formation (Figure 6 ).
DISCUSSION
Both fragments a and b had the same N-terminal amino acid sequence, which corresponds to the N-terminus of angiostatin and was identical to that of the starting material, Lys-plasminogen. The molecular masses of fragments a and b, as determined by SDSelectrophoresis, were 44.5 kDa and 41 kDa respectively. This is large enough to cover the kringle domains 1-4 (approximately 370 amino acids), of which angiostatin consists (Figure 3) . Since fragment c resulted from a unique cleavage of peptide bond Glu439-Ala440, which is located between kringles 4 and 5, it is most likely that both fragments a and b have identical amino acid backbones spanning from Lys78 to Glu439, for which a calculated molecular mass of 41.2 kDa would be expected. The difference in molecular mass between fragments a and b is attributable to a variable glycosylation of plasminogen at Asn289: only 50% of plasminogen molecules are glycosylated at this site with 10-11 monosaccharide units (Hayes and Castellino, 1979) .
The molecular mass of fragment c was determined by SDS-electrophoresis as 38 kDa. This corresponds to a calculated molecular mass of 38.5 kDa for the remainder of the plasminogen molecule, spanning from Ala440 to the C-terminal Asn791, comprising kringle 5 and the catalytic domain and resembling miniplasminogen (Sottrup-Jensen et al, 1978) .
We concluded that both fragments a and b correspond to angiostatin and are generated from Lys-plasminogen by cleavage of a single peptide bond between kringles 4 and 5 by PSA. The affinity-purified fragments a and b had angiostatin-like activity as shown by the inhibition of tubular formation and proliferation of HUVECs in the in vitro morphogenesis assays.
Fragment c, the remaining part of plasminogen, was not cleaved at Arg561, indicating that activation of plasminogen to plasmin had not taken place. This distinguishes the action of PSA on plasminogen from the mechanism described by Gately et al (1996) , who showed that human prostate carcinoma cell lines PC-3, DU-145 and LNCaP express enzymatic activity that can generate bioactive angiostatin from plasminogen. They did not attribute this activity to PSA, however, which is only secreted in significant amounts from LNCaP (Hasenson et al, 1989) . Rather, they identified urokinase released by PC-3 cells to be sufficient for angiostatin generation by autocatalysis of plasmin -however, only in the presence of free sulphydryl donors (Gately et al, 1997) . Thus, it seems that some prostate cancer cells may have two different means of angiostatin generation: urokinase, which requires strong reducing agents for artificial disruption of intramolecular disulphide-bridges and the activation of plasmin, and PSA, which does not. Considering the specificity of PSA for the extracorporal catalysis of semenogelin, there being no known physiological intracorporal substrate for PSA, dystopic release of PSA in prostate cancer could theoretically lead to paraneoplastic formation of angiostatin-like activity. Thus, we interpret our finding not as a physiological but rather an erroneous, pathophysiological process, which imitates angiostatin generation by the ubiquitous macrophage proteinases.
Different enzymes are capable of conversion of plasminogen to angiostatin. Dong et al (1997) showed a role for macrophage metalloelastase (MME) in the generation of angiostatin in Lewis lung carcinoma. In vitro, matrix metalloproteinase MMP-9 cleaves between kringles 4 and 5 at peptide bond Pro446-Pro447 (Patterson and Sang, 1997) , and MMP3 (Lijnen et al, 1998) as well as MMP-7 (Patterson and Sang, 1997) both cleave at the neighbouring peptide bond, Pro447-Val448. This is 7-8 amino acids downstream from the cleavage site of PSA observed by us. Pancreatic elastase cleavage sites were mapped to Val449-Val450 and Leu451-Pro452 (Cao et al, 1997) . Specificity of the PSAcleavage site in our experiments was confirmed by the fact that it was completely distinct from any other known proteinase cleavage site in this domain.
Apparently, the scissile peptide chain between kringles 4 and 5 is exposed to the surface of the plasminogen molecule, allowing for proteolytic attack by proteinases of different specificities and classes. This resembles the bait region in α-2-macroglobulin (Sottrup-Jensen et al, 1981) . The cleavage site of PSA in this area is novel and has not been described for any other enzyme. Since several forms of angiostatin-like plasminogen fragments with microheterogeneity in this scissile connection peptide region between kringles 4 and 5 are generated by different proteinases, angiostatin may be no longer considered a single entity. Rather, there are multiple isoforms depending on the mechanism of generation.
We showed for the first time that PSA purified from human seminal plasma specifically interacts with plasminogen to form angiostatin-like fragments from plasminogen in a defined, cellfree system. However, the physiological role of this finding remains elusive. Is PSA released by prostate cancers likely to get in contact with large plasma proteins like plasminogen? Alpha-2-macroglobulin is the major inhibitor of PSA when it reaches the bloodstream (Leinonen et al, 1996) . Some PSA in the plasma of prostate cancer patients is complexed with α-2-macroglobulin, requiring that at least some PSA released from prostate cancer enters the bloodstream in active form. Therefore, PSA may theoretically react with plasminogen before being inhibited by plasma proteinase inhibitors. Further, in areas of invasive cancer, plasma extravasation may take place, with molecules like plasminogen (92 kDa) diffusing more readily than the very large α-2-macroglobulin (800 kDa). Local concentrations of PSA in tumour tissue may be sufficiently high to cause proteolysis of plasminogen. Even after prolonged incubation, the fragments from limited PSA proteolysis were not degraded any further.
In the future, it will be interesting to determine whether generation of angiostatin by PSA actually does occur in vivo. Since angiostatin can induce and sustain dormancy of tumours (O'Reilly et al, 1996) , our findings might help to understand the general clinical observation that prostate cancer has a very low progression rate.
